Sanofi(US:SNY) 智通财经网·2025-07-22 11:00Group 1 - Sanofi has agreed to acquire UK biotech company Vicebio Ltd. for up to $1.6 billion, which includes an upfront payment of $1.15 billion and potential milestone payments of up to $450 million [1] - The acquisition aims to enhance Sanofi's vaccine development capabilities, particularly for a new generation of vaccines that can protect against multiple respiratory viruses in a single injection [1][2] - Despite skepticism about vaccine uptake from U.S. health officials, pharmaceutical companies continue to invest in vaccine research and development [1] Group 2 - Vicebio's technology, known as "molecular clamps," accelerates the development of liquid combination vaccines that can be stored at refrigerator temperatures, simplifying production and distribution [2] - The company is currently developing a single vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which is in early exploratory clinical trials [2] - Sanofi's CEO, Paul Hudson, is focused on expanding the product line to ensure future revenue streams that can replace income from blockbuster drugs like Dupixent [3]